Trending...
- YieldOMega Launches $DOUB Airdrop Campaign Ahead of TimeCurve Launch
- CAPO Supply Announces Opening of Second Location in New Castle, Pennsylvania
- $224 Billion Growing Market in Life Settlements Presents Major Opportunity for New Policy Acquisition Business Plan: DLT Resolution Stock Symbol: DLTI
TAEUS® Technology Delivers MRI-Level Liver Fat Measurement at the Point of Care for Disease Affecting 30% of Adults Worldwide: $NDRA
ANN ARBOR, Mich. - PrAtlas -- ENDRA Life Sciences Inc. (N A S D A Q: NDRA) is advancing a potentially transformative diagnostic technology aimed at addressing one of the fastest-growing global health challenges—Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
With MASLD now estimated to affect approximately 30% of adults worldwide, the demand for accurate, accessible, and affordable diagnostic tools has never been greater. ENDRA's proprietary Thermo Acoustic Enhanced UltraSound (TAEUS®) technology is being developed to fill that gap by delivering MRI-level measurement capabilities directly at the point of patient care, but at a fraction of the cost.
Recent clinical study results suggest the company's TAEUS® Liver device may offer the precision of expensive imaging modalities combined with the convenience and scalability of ultrasound systems, positioning the technology as a potential game-changer in liver disease detection and monitoring.
Favorable Clinical Study Results Demonstrate Strong Measurement Consistency
TAEUS® Liver Achieves "Good to Excellent" Reliability Metrics for Long-Term Disease Monitoring
On February 26, ENDRA reported encouraging data from a clinical study evaluating the measurement consistency of the TAEUS® Liver device, a key milestone for its development as a diagnostic tool for monitoring MASLD.
The study assessed the platform's performance in real-world clinical settings, examining both repeatability and reproducibility, two critical indicators for diagnostic reliability and regulatory acceptance.
Key findings from the study included:
These metrics fall within the "good to excellent" performance range, demonstrating strong consistency across multiple operators and repeated scans.
The clinical trial involved 14 subjects and 56 independent measurements, with multiple operators performing scans to simulate real-world clinical workflows. The resulting data were analyzed using Gage Repeatability and Reproducibility (R&R) methodology, which determines how much variability stems from the measurement system itself versus actual biological differences among patients.
More on PrAtlas
The results indicate that the TAEUS® platform can deliver highly reliable liver fat measurements regardless of the clinician performing the scan.
A Massive Global Disease Market with Limited Diagnostic Tools
MASLD Impacts More Than Two Billion People Worldwide
Metabolic dysfunction-associated steatotic liver disease represents a massive and growing healthcare challenge.
Closely linked to obesity, diabetes, and metabolic syndrome, MASLD is estimated to affect over two billion people globally, making it one of the most prevalent chronic liver conditions in the world.
Despite its scale, diagnostic tools remain limited.
While MRI-PDFF imaging is considered the gold standard for measuring liver fat, the technology is expensive and not widely accessible for routine patient monitoring. This creates a significant barrier for clinicians seeking to track disease progression or treatment effectiveness.
ENDRA's TAEUS® platform is designed to solve this problem by providing MRI-quality liver fat quantification using ultrasound-based systems, enabling faster, lower-cost testing directly in clinical settings.
Addressing the Limitations of Traditional Ultrasound Imaging
TAEUS® Delivers Objective, Quantitative Measurements
Traditional ultrasound techniques are commonly used in liver assessments but suffer from high inter-observer variability and subjective interpretations, which can limit their effectiveness for precise disease monitoring.
ENDRA's TAEUS® technology is designed to overcome these limitations.
By combining thermoacoustic imaging physics with ultrasound systems, the platform provides quantitative measurement of tissue fat content, enabling clinicians to detect subtle changes in liver fat levels with greater consistency.
This capability is particularly important as new metabolic therapies emerge, where small, incremental improvements in liver fat levels may determine treatment effectiveness.
The ability to detect these changes without relying on repeated MRI scans could significantly improve both patient monitoring and healthcare cost efficiency.
Potential Applications Extend Across Clinical Practice and Drug Development
Pharmaceutical Companies May Utilize TAEUS® for Clinical Trials and Patient Monitoring
The potential applications of ENDRA's technology extend beyond routine clinical care.
More on PrAtlas
Pharmaceutical companies developing therapies for metabolic and liver diseases require reliable diagnostic tools to identify eligible patients, monitor treatment progress, and evaluate therapeutic outcomes during clinical trials.
TAEUS® could provide an attractive solution by offering frequent, affordable liver fat measurements that would otherwise require expensive MRI imaging.
This capability could make the platform valuable for:
As new treatments for metabolic liver disease enter the market, the need for repeatable and cost-efficient diagnostic monitoring tools is expected to grow significantly.
ENDRA's Technology Strategy Combines Precision with Practical Deployment
MRI-Level Insights Delivered Through Ultrasound-Based Systems
ENDRA's approach centers on merging the precision of advanced imaging technologies with the accessibility of ultrasound platforms already widely used in healthcare facilities.
By integrating thermoacoustic technology into ultrasound systems, TAEUS® is designed to provide:
This combination could allow healthcare providers to expand screening, improve disease monitoring, and potentially detect liver disease earlier.
Positioned to Address a Large and Growing Global Market
With metabolic diseases rising globally, the demand for scalable diagnostic technologies is increasing rapidly.
ENDRA Life Sciences is positioning its TAEUS® platform to address a massive global population affected by liver disease, offering a diagnostic approach that aims to bridge the gap between high-cost imaging systems and widely accessible ultrasound devices.
If adoption continues to grow, TAEUS® could represent an important advancement in how clinicians identify, monitor, and manage chronic liver disease.
For more information, visit:
www.endrainc.com
Media Contact
ENDRA Life Sciences, Inc. (N A S D A Q: NDRA)
Yvonne Briggs – Investor Relations
investors@endrainc.com
ybriggs@allianceadvisors.com
(310) 691-7100
United States
Website: www.endrainc.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
With MASLD now estimated to affect approximately 30% of adults worldwide, the demand for accurate, accessible, and affordable diagnostic tools has never been greater. ENDRA's proprietary Thermo Acoustic Enhanced UltraSound (TAEUS®) technology is being developed to fill that gap by delivering MRI-level measurement capabilities directly at the point of patient care, but at a fraction of the cost.
Recent clinical study results suggest the company's TAEUS® Liver device may offer the precision of expensive imaging modalities combined with the convenience and scalability of ultrasound systems, positioning the technology as a potential game-changer in liver disease detection and monitoring.
Favorable Clinical Study Results Demonstrate Strong Measurement Consistency
TAEUS® Liver Achieves "Good to Excellent" Reliability Metrics for Long-Term Disease Monitoring
On February 26, ENDRA reported encouraging data from a clinical study evaluating the measurement consistency of the TAEUS® Liver device, a key milestone for its development as a diagnostic tool for monitoring MASLD.
The study assessed the platform's performance in real-world clinical settings, examining both repeatability and reproducibility, two critical indicators for diagnostic reliability and regulatory acceptance.
Key findings from the study included:
- Intraclass Correlation Coefficient (ICC): 0.89
- Standard Error of Measurement (SEM): 3.3%
These metrics fall within the "good to excellent" performance range, demonstrating strong consistency across multiple operators and repeated scans.
The clinical trial involved 14 subjects and 56 independent measurements, with multiple operators performing scans to simulate real-world clinical workflows. The resulting data were analyzed using Gage Repeatability and Reproducibility (R&R) methodology, which determines how much variability stems from the measurement system itself versus actual biological differences among patients.
More on PrAtlas
- D.R. Crotzer Announces A New Science Fiction Book Series Exploring Life Energy, Dreams, and the Mystery of Existence
- Color Card Administrator Highlights Growing Enterprise Demand for Operational Infrastructure in Business Card Identity Governance
- American Properties Celebrates Grand Opening and Ribbon Cutting Ceremony at Heritage at South
- Crosswalk Ministries USA Announces 2026 Child and Family Well-Being Conference in Stockbridge, Georgia
- Research reveals "The Borderless Pay Standard," a 48-point gap between multinational employers and workers on transparent pay expectations
The results indicate that the TAEUS® platform can deliver highly reliable liver fat measurements regardless of the clinician performing the scan.
A Massive Global Disease Market with Limited Diagnostic Tools
MASLD Impacts More Than Two Billion People Worldwide
Metabolic dysfunction-associated steatotic liver disease represents a massive and growing healthcare challenge.
Closely linked to obesity, diabetes, and metabolic syndrome, MASLD is estimated to affect over two billion people globally, making it one of the most prevalent chronic liver conditions in the world.
Despite its scale, diagnostic tools remain limited.
While MRI-PDFF imaging is considered the gold standard for measuring liver fat, the technology is expensive and not widely accessible for routine patient monitoring. This creates a significant barrier for clinicians seeking to track disease progression or treatment effectiveness.
ENDRA's TAEUS® platform is designed to solve this problem by providing MRI-quality liver fat quantification using ultrasound-based systems, enabling faster, lower-cost testing directly in clinical settings.
Addressing the Limitations of Traditional Ultrasound Imaging
TAEUS® Delivers Objective, Quantitative Measurements
Traditional ultrasound techniques are commonly used in liver assessments but suffer from high inter-observer variability and subjective interpretations, which can limit their effectiveness for precise disease monitoring.
ENDRA's TAEUS® technology is designed to overcome these limitations.
By combining thermoacoustic imaging physics with ultrasound systems, the platform provides quantitative measurement of tissue fat content, enabling clinicians to detect subtle changes in liver fat levels with greater consistency.
This capability is particularly important as new metabolic therapies emerge, where small, incremental improvements in liver fat levels may determine treatment effectiveness.
The ability to detect these changes without relying on repeated MRI scans could significantly improve both patient monitoring and healthcare cost efficiency.
Potential Applications Extend Across Clinical Practice and Drug Development
Pharmaceutical Companies May Utilize TAEUS® for Clinical Trials and Patient Monitoring
The potential applications of ENDRA's technology extend beyond routine clinical care.
More on PrAtlas
- Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
- Lansdowne Photographer Steven Weisz Selected for Philadelphia City Hall Exhibition
- Federal indictments bring new scrutiny to SPLC practices and highlight the real‑world impact of its designations on nonprofit groups, including NCFM
- Shedrack Anderson Releases New Album
- Could You Make a 2026 World Cup Squad? A New Free Tool Will Tell You Where You'd Sit on Any National Team's Bench in 90 Seconds
Pharmaceutical companies developing therapies for metabolic and liver diseases require reliable diagnostic tools to identify eligible patients, monitor treatment progress, and evaluate therapeutic outcomes during clinical trials.
TAEUS® could provide an attractive solution by offering frequent, affordable liver fat measurements that would otherwise require expensive MRI imaging.
This capability could make the platform valuable for:
- Patient recruitment for clinical trials
- Monitoring therapeutic effectiveness
- Long-term disease management in clinical practice
As new treatments for metabolic liver disease enter the market, the need for repeatable and cost-efficient diagnostic monitoring tools is expected to grow significantly.
ENDRA's Technology Strategy Combines Precision with Practical Deployment
MRI-Level Insights Delivered Through Ultrasound-Based Systems
ENDRA's approach centers on merging the precision of advanced imaging technologies with the accessibility of ultrasound platforms already widely used in healthcare facilities.
By integrating thermoacoustic technology into ultrasound systems, TAEUS® is designed to provide:
- Quantitative measurement of liver fat
- High repeatability across operators
- Cost-effective point-of-care deployment
- Improved accessibility for large patient populations
This combination could allow healthcare providers to expand screening, improve disease monitoring, and potentially detect liver disease earlier.
Positioned to Address a Large and Growing Global Market
With metabolic diseases rising globally, the demand for scalable diagnostic technologies is increasing rapidly.
ENDRA Life Sciences is positioning its TAEUS® platform to address a massive global population affected by liver disease, offering a diagnostic approach that aims to bridge the gap between high-cost imaging systems and widely accessible ultrasound devices.
If adoption continues to grow, TAEUS® could represent an important advancement in how clinicians identify, monitor, and manage chronic liver disease.
For more information, visit:
www.endrainc.com
Media Contact
ENDRA Life Sciences, Inc. (N A S D A Q: NDRA)
Yvonne Briggs – Investor Relations
investors@endrainc.com
ybriggs@allianceadvisors.com
(310) 691-7100
United States
Website: www.endrainc.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: CorporateAds
0 Comments
Latest on PrAtlas
- The AI Production Shift: Why Game Development Is Entering Its Most Accelerated Phase
- World-First AI Humanoid Robot Debuts on Cherie Barber's Ground-breaking Australian Reno Show
- New Survey Reveals America's Most Feared Bridges for Cyclists — Golden Gate Tops the List
- Raymond Lavine, Extended Care Benefits Advisor and Author, to Appear on National Television Series Moving America Forward
- NaturismRE Launches Structured Nudism & Naturism Encyclopedia, Aiming to Reframe Public Understanding
- AI Is Closing the Gap Between Offshore Virtual Assistants and Onshore Staff
- CCHR Highlights Concerns Over Coercive and Failed $140 Billion Mental Health Practices at Psychiatric Convention
- Avery Headley Leads Major Stabilization and Modernization Initiative Across Bronx Affordable Housing Portfolio
- NewReputation's AI Sentiment Analysis Tool Reaches 2,500 Users as Businesses Demand Clearer Brand Intelligence
- CAPO Supply Announces Opening of Second Location in New Castle, Pennsylvania
- $224 Billion Growing Market in Life Settlements Presents Major Opportunity for New Policy Acquisition Business Plan: DLT Resolution Stock Symbol: DLTI
- Fyt-02 Launches on Kickstarter The Smart Sensor That Turns Any Chair Into a Posture & Movement Track
- YieldOMega Launches $DOUB Airdrop Campaign Ahead of TimeCurve Launch
- Kaltra Expands Microchannel Water Coil Line for U.S. HVAC Market With New Corrosion-Resistant Tube Technology
- Collectibles EvoRelic Celebrates Stellar 4.8-Star Customer Rating
- Phoenix Hip-hop Artist Rhymi Hits 23k Monthly Listeners 12 Days After Album Release
- Pediatrician Launches "Confessions of a Detective Doctor" Children's Book Series
- Integrated Maintenance Platforms Are Transforming Aircraft Operations
- T. Jones Group's Cameron Jones Serves as Judge for the 2026 CHBA National Awards for Housing Excellence
- Derek Advanced Tracking Systems Revolutionizes Asset Monitoring with Advanced Technology